Functional magnetic resonance imaging for defining the biological target volume.

Department of Radiology, Innovative Cancer Diagnostics and Therapy, German Cancer Research Center, Heidelberg, Germany.
Cancer Imaging (Impact Factor: 1.29). 02/2006; 6:51-5. DOI: 10.1102/1470-7330.2006.0010
Source: PubMed

ABSTRACT Morphology as demonstrated by CT is the basis for radiotherapy planning. Intensity-modulated and adaptive radiotherapy techniques would greatly benefit from additional functional information allowing for definition of the biological target volume. MRI techniques include several which can characterize and quantify different tissue properties and their tumour-related changes. Results of perfusion MRI represent microvascular density and permeability; MR spectroscopy depicts particular metabolites; diffusion weighted imaging shows tissue at risk and tumour cellularity; while dynamic 3D acquisition (4D MRI) shows organ motion and the mobility of tumours within them.

  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: With the recent introduction of PET/MRI, we investigated whether diffusion-weighted imaging (DWI) can complement PET for predicting local treatment response in Hodgkin lymphoma. METHODS: This retrospective study included 39 patients selected from a hospital database with a histological diagnosis of Hodgkin lymphoma undergoing whole-body MRI (supplemented by DWI) and PET/CT before and after two cycles of vincristine, etoposide, prednisolone and doxorubicin (OEPA). The pretreatment volume, MRI apparent diffusion coefficient (ADC) and PET maximum standardized uptake value (SUV(max)) of the largest nodal mass were determined quantitatively for evaluation of the local response following two cycles of OEPA. Quantitative pretreatment imaging biomarkers (disease volume, ADC, SUV(max)) were compared between sites with an adequate and those with an inadequate response using Fisher's exact test and Mann Whitney statistics. Multivariate models predictive of an inadequate response based on demographic/clinical features, pretreatment disease volume and SUV(max) without (model 1) and with (model 2) the addition of ADC were derived and crossvalidated. The ROC area under curve (AUC) was calculated for both models using the full dataset (training) and the crossvalidation (test) data. RESULTS: Sites with an adequate response had a significantly lower median pretreatment ADC (1.0 × 10(-3)mm(2)s(-1)) than those with an inadequate response (1.26 × 10(-3)mm(2)s(-1); p < 0.01). There were no significant differences in patient demographic/clinical parameters, pretreatment SUV(max) or pretreatment nodal volume between sites with inadequate and adequate response. The ROC-AUCs for prediction of an inadequate response for the training and test data for model 1 were 0.90 and 0.53, and for model 2 were 0.84 and 0.71, respectively. CONCLUSION: DWI complements PET for prediction of site-specific interim response to chemotherapy.
    European Journal of Nuclear Medicine 11/2012; 40(3). DOI:10.1007/s00259-012-2293-7 · 4.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular imaging fundamentally changes the way we look at cancer. Imaging paradigms are now shifting away from classical morphological measures towards the assessment of functional, metabolic, cellular, and molecular information in vivo. Interdisciplinary driven developments of imaging methodology and probe molecules utilizing animal models of human cancers have enhanced our ability to non-invasively characterize neoplastic tissue and follow anti-cancer treatments. Preclinical molecular imaging offers a whole palette of excellent methodology to choose from. We will focus on positron emission tomography (PET) and magnetic resonance imaging (MRI) techniques, since they provide excellent and complementary molecular imaging capabilities and bear high potential for clinical translation. Prerequisites and consequences of using animal models as surrogates of human cancers in preclinical molecular imaging are outlined. We present physical principles, values and limitations of PET and MRI as molecular imaging modalities and comment on their high potential to non-invasively assess information on hypoxia, angiogenesis, apoptosis, gene expression, metabolism, and cell trafficking in preclinical cancer research.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 01/2013; 187:257-310. DOI:10.1007/978-3-642-10853-2_9
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a new approach for potential monitoring of tumor burden in experimental animals using multichannel in vivo flow cytometry, a novel optical technique that enables the realtime, continuous detection and quantification of fluorescently labeled cells in the circulation without the need for blood extraction. The ability to non-invasively track circulating cells in real time and in their native environment, opens up enormous possibilities for new investigations into the mechanisms that govern the complex trafficking and tissue interactions of these cells in a wide range of clinical and biological fields such as cancer, stem cell biology and immunology. We have developed the in vivo flow cytometer in order to track circulating cancer cells in a mouse model and provide a new, non-invasive method for the monitoring of cancer disease progression as well as the response to therapeutic intervention.
    Bioinformatics & Bioengineering (BIBE), 2012 IEEE 12th International Conference on; 01/2012


1 Download
Available from